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Abstract 
Drug-induced cardiotoxicity remains a primary reason why new pharmaceutical 
compounds are withdrawn from clinical trials and the consumer market. Many current 
cardiotoxicity screening devices utilize two-dimensional monolayers of cells, which are not a 
representative model of the heart, resulting in poor detection of cardiotoxic compounds. Current 
methods are also time-consuming and expensive.  We have developed a novel cardiotoxicity 
screening device that utilizes cardiomyocytes seeded on fibrin microthreads to form a three-
dimensional model for cardiac tissue. Our device can be used with standard laboratory 
equipment to analyze the contractile properties of these seeded threads. Upon the addition of 
pharmaceutical agents, the device has the potential to detect changes in contraction and thus 
identify cardiotoxic compounds. The device is also easy to use, inexpensive, and biocompatible. 
In the future, this prototype can improve the detection of cardiotoxic drugs, saving time and 
money in the drug development process to ultimately increase the safety of drugs on the market 
for consumers. 
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Chapter 1: Introduction 
Drug-induced cardiotoxicity is one of the main reasons newly developed drugs are 
eliminated from pre-clinical and full clinical trials. Over the last thirty years, twenty-eight 
percent of all drug withdrawals in the United States have been due to adverse cardiac effects, 
putting medication consumers at risk and posing serious financial and legal consequences for 
pharmaceutical companies. Almost every class of therapeutic drugs has caused harmful side 
effects on the heart, including powerful anti-cancer agents as well as everyday over the counter 
antihistamines and nonsteroidal anti-inflammatory drugs (NSAIDS) (Crivellente, 2011). 
Cardiotoxic drugs cause weakness in cardiomyocyte activity to produce a variety of heart 
diseases, ranging from reversible arrhythmias to permanent cardiomyopathy. Because of the high 
occurrence of drug failure due to harmful cardiac side effects, there is both a market and 
consumer need for innovative in vitro assays that enable earlier, more accurate detection of 
cardiotoxic compounds. Pharmaceutical companies require faster and more reliable screening 
systems to save time and money in the drug development process whereas patients who require 
all types of medication are in need of safer drugs as well as more drug options that better suit 
their unique medical and personal needs to improve their quality of life. 
Engineers and scientists have developed several methods to screen for drug-induced 
changes in cardiac tissue properties and functions. These methods have demonstrated the ability 
to detect changes in cardiac cell contraction strength, contraction frequency, and relative tissue 
death. However, these technologies do not fully meet the needs of pharmaceutical companies 
because they exhibit limitations in terms of accuracy, data acquisition time, biocompatibility, and 
cost. Specifically, most drug-screening systems are based on 2-D monolayer cell culture, which 
is an inaccurate model that does not completely mimic the complex cell-cell and cell-matrix 
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interactions of the 3-D in vivo cardiac tissue environment (Moya et al, 2013). While other drug 
screening platforms may incorporate a more realistic 3-D model, they are otherwise limited in 
their efficiency. For example, some systems use the technique of high-content screening (HCS), 
which detects minute intracellular changes through the use of fluorescence microscopy and 
multi-parameter software analysis (Vandenburgh, et al., 2008). Although HCS is ideal for 
producing reliable results, it is not a practical option to meet the high demand of new and 
improved drugs because it requires special, expensive equipment and takes a very long time to 
acquire data. Additionally, current screening protocols may exhibit biocompatibility issues as 
their assembly methods often negatively impact cell health and proliferation, which can affect 
cell contraction strength and other properties (Eschenhagen and Zimmerman, 2005). To improve 
upon current drug screening technologies, there is a need for inexpensive, less complex systems 
based on three-dimensional tissue constructs that better mimic the cell-to-cell interactions and 
functionality of native cardiac tissue to serve as a more accurate model when measuring 
contractile strength of cells and screening for the effects of pharmaceutical agents. 
Regarding a more accurate model system for in vitro cardiac assessment, cell-seeded 
biological sutures used for cell therapy also show great promise in serving as 3-D tissue models. 
This project utilizes fibrin microthreads, a newly developed cell therapy technology used to treat 
infarcted heart tissue. Researchers at Worcester Polytechnic Institute (WPI) have demonstrated 
that human mesenchymal stem cells (hMSCs) can be seeded on fibrin microthread sutures for 
reliable cell delivery to areas of cardiac infarction. Delivered stem cells have the capacity to 
differentiate into new cardiac cells and organize into muscle fibers and connective tissue, 
restoring heart function (Dominko, et al. 2011). These threads can also be loaded with growth 
factors to promote cell outgrowth and proliferation (Cornwell and Pins, 2010). Fibrin 
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microthreads have demonstrated the ability to greatly improve the alignment of cardiac 
fibroblasts along the suture axis, suggesting that the suture scaffold promotes the development of 
a three-dimensional tissue structure that can serve as a more accurate model for in vivo cardiac 
tissue than current two-dimensional models (Guyette, et al. 2013). 
Our goal was to develop a drug-screening system utilizing fibrin microthreads as a three-
dimensional model to better mimic cardiac tissue in vivo. The microthreads should allow for the 
seeding of cardiac myocytes and/or stem cells which contract upon electrical stimulation. Our 
device should be able to measure and collect this contractile data to allow for the high throughput 
screening of various added pharmaceutical compounds. The final system should generate 
accurate and reproducible results and be biocompatible and sterilizable. It should also be easy to 
use in terms of adding and removing the microthread bundles and pharmaceutical agents. 
Finally, the device should be safe to use and cost effective.  
To meet the goals of our project, we utilized inexpensive, reusable, readily available 
materials to develop a non-complex device that could be used in conjunction with common 
laboratory equipment. We developed an attachment system that reliably held the cell-seeded 
fibrin bundles in place and also allowed for the application of electrical stimulation. We 
developed a unique design that allowed for the capture of high quality images in order to easily 
evaluate the contractile behavior of the fibers. Several tests were performed to confirm the 
biocompatibility and reliability of the final device. 
In the following chapters, substantial background is provided for topics related to our 
project including most importantly cardiac biology, cardiotoxicity, and microthread technology. 
An overview of our strategy and various approaches for the development of our device is also 
given. A description of our alternative conceptual and preliminary designs is provided, followed 
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by detailed explanations and illustrations of our current design. We also provide the various 
verification and validation tests conducted to confirm the success of our device as well as a 
discussion of our results. Finally, conclusions are made about our project followed by 
recommendations to improve upon our design in the future. 
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Chapter 2: Background  
Before we begin to generate design alternatives, it is first critically important to fully 
understand the problem our project addresses. In the following sections, we outline the 
contractile biology of the heart as a whole organ as well as at the cellular level, and then describe 
the various pharmaceutical agents and consequences associated with cardiotoxicity. Following 
this technical background, we summarize some current screening methods and their limitations. 
Finally, we discuss the fibrin microthread model system and cell types we will be implementing 
in our design, and how specific agents affect the contractile mechanisms of these cells. 
2.1 In vitro Cardiac Function 
The heart provides constant circulation of blood in order to ensure a continuous supply of 
nutrients and removal of waste from the body. This organ is divided into left and right halves that 
serve as transport pumps that contract to circulate blood throughout the body.  Each half consists 
of an atrium and a ventricle. The right atrium receives deoxygenated blood from the body, which 
flows through the tricuspid valve and into the right ventricle. Here, the blood is pumped into the 
pulmonary arteries, which carry blood through the pulmonary circuit to the lungs, where it is 
oxygenated. This newly oxygen enriched blood is then received by the left atrium and passed to 
the left ventricle, where it is again pumped out of the heart, this time delivered through the 
systemic circuit to the rest of the body, completing the cycle (Figure 2.1). In this manner, the 
heart transports oxygen and nutrients throughout the body and also helps to remove waste 
(Marieb and Hoehn, 2010). 
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Cardiac Blood Flow. Feb 24 2013. <http://forgottenphysiology.com/2013/02/24/the-zen-of-cardiac-blood-flow/>. 
Figure 2.1: Diagram of blood flow through heart 
The heart wall is composed of three layers: the epicardium, myocardium, and 
endocardium. The epicardium, the outermost layer of the heart wall, is the visceral layer of the 
pericardium, which is the double-wall sac that serves as an enclosure for the heart. The 
myocardium is the layer responsible for contraction and is composed primarily of cardiac 
muscle, forming the majority of the heart itself. The third layer is the endocardium, which is 
located on the inner myocardial surface and lines the heart chambers (Marieb and Hoehn, 2010).   
         Cardiac muscle fibers, that make-up the myocardium, work to perform the contraction 
necessary for blood to be pumped throughout the body. Cardiac muscle is striated and contracts 
by the sliding filament mechanism, a method very similar to that of skeletal muscle (Figure 2). 
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Cummings, Benjamin. Stages of a Muscle Contraction.  Addison Wesley Longman, Inc. 
<http://legacy.owensboro.kctcs.edu/gcaplan/anat/notes/api%20notes%20j%20%20muscle%20contraction.htm>. 
Figure 2.2: Sliding Filament Mechanism for muscle contraction 
Cardiac cells are short, thick, and interconnected. Each cell has one or more nuclei, while 
a connective tissue matrix called the endomysium fills intercellular spaces (Figure 3). This 
matrix is connected to the fibrous cardiac skeleton, a network of collagen and elastin, which 
reinforces the myocardium and anchors cardiac muscle fibers. This skeleton provides a structure 
for these fibers to pull against and exert their force (Marieb and Hoehn, 2010). 
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Cardiac Muscle Cell Structure. 2014. <http://www.paradoja7.com/cardiac-muscle-cell-structure/>. 
Figure 2.3: Structure of typical heart muscle 
         The contraction of cardiac muscle by the sliding filament mechanism is triggered by 
action potentials traveling across the cell membranes. Roughly one percent of cardiac fibers have 
the ability to depolarize spontaneously. It is this autorhythmic quality that gives these fibers the 
ability to pace the heart. The rest of the myocardium is composed of contractile muscle fibers 
that allow the heart to pump blood throughout the body. Contraction occurs due to a series of 
regulated steps. Depolarization first results in the influx of Na+ ions through fast-gated Na+ 
channels. This causes an increase in the action potential from -90 mV to about 30 mV. This 
depolarization wave is then transmitted down the T tubules, causing the release of Ca2+ into the 
sarcoplasm. This influx of Ca2+ then causes the sliding of myofilaments through cross bridge 
activation. The cells continue to contract as long as Ca2+ continues to enter the sarcoplasm. In 
order for repolarization to occur, Ca2+ channels are deactivated and Ca2+ re-enters the 
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sarcoplasmic reticulum. Simultaneously, K+ channels are opened and there is a rapid loss of K+ 
from the cells (Marieb and Hoehn, 2010). Because this mechanism stimulates contraction of 
cardiac muscles fibers, an increase in Ca2+ can cause a greater contraction. 
2.2 Cardiac Cell Biology 
The myocardium is able to function and contract as one unit because of the cell-to-cell 
adhesion found in cardiomyocytes, which is made possible by intercalated disks (ICDs). These 
disks are composed of three major complexes – desmosomes, fascia adherens, and gap junctions 
(Figure 4).   
 
Conduction Fibers. 2011. Pearson Education, Inc. 
<http://droualb.faculty.mjc.edu/Course%20Materials/Physiology%20101/Chapter%20Notes/Fall%202011/chapter_13%20Fall%
202011.htm>. 
Figure 2.4: Diagram of intercalated disk 
Together, desmosomes and fascia adherens are responsible for mechanically reinforcing 
and coupling cardiomyocytes while gap junctions are utilized for proper electrical conduction 
between the cells (Sheikh, et al. 2009). These three structures work together to maintain the 
structural integrity and synchronized contraction of the myocardium, allowing it to behave as a 
single coordinated unit, known as a functional syncytium (Marieb and Hoehn, 2010).  
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Desmosomes serve to anchor the cardiac cellular membranes to the fibrous cardiac skeleton, 
which is particularly important in areas of constant stress, as caused by the rhythmic beating of 
the heart. Fascia adherens work in a similar manner, but instead anchor cells by linking the 
membrane with the actin cytoskeleton. Gap junctions form aqueous pores between cells, which 
allow for electrical and metabolic connections between two adjoining cells. Thus, gap junctions 
are responsible for the coordinated contraction of all cardiac muscle cells as a single contractile 
unit (Sheikh, et al. 2009). Each of these complexes is composed of several unique proteins that 
together allow the ICDs to perform their overall function. Across these complexes, these proteins 
have been known to exercise cellular “crosstalk”. This “crosstalk” occurs because of the “close 
spatial proximity of the junctional complexes to one another” and also because these proteins 
share common binding partners (Sheikh, et el. 2009). 
Data supports the notion that changes in the mechanical junctions of ICDs have a 
negative impact on the electrical functionality of cardiac cells (Noorman, et al. 2009). For this 
reason, it is important that any in vitro model for cardiac tissue closely mimics the mechanical 
structure found in natural heart tissue. If this is not the case, electrical conductivity and thus 
contraction of cardiac cells will not occur as they do in vivo. Therefore, three-dimensional 
models for cardiac in vitro testing should be highly preferred over two-dimensional models that 
do not mimic the mechanical junctions of the ICDs in the cardiomyocytes of the myocardium.   
2.3 Cardiotoxicity  
Cardiotoxicity is the event of heart damage caused by medication. The list of possible 
drug-related heart complications is extensive, including rapid heart rate, arrhythmia, myocarditis, 
coronary thrombosis, myocardial infarction, cardiomyopathy, and heart failure. There are two 
types of cardiotoxicities. Type I is the most serious and causes permanent damage to the 
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myocardium, while type II results in cardiac damage that is usually reversible. Cardiotoxic 
effects caused by type I agents are related to the cumulative dose of a drug and cause irreversible 
injuries to the heart tissue such as vacuoles, necrosis, and sarcomere disruption. Conversely, 
heart injury caused by type II agents is not related to dose and does not lead to harmful 
alterations in cardiac structure. To prevent the presence of these agents on the market, improved 
methods are needed that detect cardiotoxicity as early as possible. 
Several classes of therapeutic drugs have generated unanticipated adverse cardiac effects, 
including chemotherapy drugs, antihistamines, and NSAIDS. One of the most studied classes of 
drugs is anti-cancer agents, of which the most common harmful side effect is cardiotoxicity. For 
example, anthracyclines (e.g. Doxorubicin) are among the most effective chemotherapy drugs. 
However, they have been identified as very dangerous type I agents that cause permanent 
cardiomyopathy even at low doses. This irreversible cell apoptosis occurs primarily due to 
oxidative stress but may also occur as a result of DNA and protein damage (Ewer, 2010). 
Trastuzumab, another well-known cancer drug, did not show any immediate signs of 
cardiotoxicity in pre-clinical studies. However, later clinical trials identified it as a type II agent, 
associated with an unanticipated high incidence of left ventricle dysfunction (Crivellente, 2011). 
In addition to causing major health problems for consumers, this high occurrence of 
cardiotoxicity results in serious setbacks for pharmaceutical companies. If a particular drug is 
found to be cardiotoxic during a clinical trial, the program is terminated and long-term 
investments are wasted. If the drug causes cardiotoxicity in consumers after it is launched into 
the market, it is recalled and companies may be sued for negligence. The most notorious 
example of the latter situation began in 1999 when the pharmaceutical company Merck marketed 
the FDA approved drug Vioxx (Rofecoxib), an NSAID used to treat rheumatoid arthritis. Vioxx 
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was prescribed to more than twenty million people, making it one of the most prescribed 
blockbuster drugs in history. On September 30th, 2004, after five years on the market, Merck 
voluntarily recalled Vioxx after the drug caused as many as 140,000 cases of serious coronary 
heart disease, of which almost half resulted in death (Prakash, 2007). Merck was accused for 
ignoring evidence of the cardiotoxic effects of Vioxx, resulting in roughly 50,000 lawsuits, 
costing the company at least 6.38 billion dollars in settlement funds (CBS News, 2011). 
Another example was the withdrawal of the antihistamine Terfenadine (Seldane). 
Terfenadine was made in 1985 by the company Hoecsht Marion Roussel (now Avantis) for the 
treatment of allergies without causing drowsiness. More than 100 million consumers used 
Terfenadine as of 1990 and in the year before it was recalled, Hoecsht Marion Roussel made 
about $440 million in drug sales worldwide (Campbell, 2010). In 1998, thirteen years after it was 
launched on the market, Terfenadine was recalled for causing several cases of cardiac 
arrhythmia. Although the company suffered from legal expenses and a steep loss of market share 
to other allergy drugs, it was able to mitigate its damages to some degree by launching Allegra, 
an antihistamine similar to Terfenadine but without the side effects.  
2.4 Current Screening Methods 
There are several existing methods that aim to detect cardiotoxicity through the collection 
of contractile data of cells in vitro. However, these technologies do not fully meet the needs of 
pharmaceutical companies because they exhibit limitations in terms of accuracy, data acquisition 
time, and cost. Specifically, most drug-screening systems are based on 2-D monolayer cell 
culture, which is an inaccurate model that does not completely mimic the complex cell-cell and 
cell-matrix interactions of the 3-D in vivo cardiac tissue environment (Moya et al, 2013). While 
other drug screening platforms may incorporate a more realistic 3-D model, they may be 
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otherwise limited in their efficiency. For example, some systems use the technique of high-
content screening (HCS), which is a very detailed and complicated process incorporating 
fluorescence microscopy and multi-parameter image analysis. Although HCS is ideal for 
producing reliable results, it is not a practical option to meet the high demand of new and 
improved drugs because it requires special, expensive equipment and takes a long time to acquire 
data. 
One type of in vitro method that screens for cardiotoxicity uses glass-tube mounting. This 
technique consists of culturing cardiac myocytes in collagen gels incorporating extracellular 
matrix from tumors (Eschenhagen and Zimmerman, 2005). This cell mixture is then mounted 
between two Velcro covered glass tubes and placed in a rectangular well. Mechanical force 
transducers are attached to these tubes to measure and record contractile force. While this system 
is effective at assembling cells for heart tissue development and the application of 
pharmaceutical agents is permitted, drawbacks of this method include the inability to observe the 
viability of specific cells as well as limited application for electrical stimulation. 
Another method is micro-post mounting, which involves the use of tissue-engineered 
three-dimensional muscle (Vandenburgh, et al., 2008). The muscle is grown and attached to 
micro-posts where it is distributed into well plates. Electrical stimulation is applied to measure 
contraction and motion. Pharmaceutical agents can then be added to monitor how cell properties 
are affected. The process of high-content screening (HCS) is used to gather data on the muscle 
tissue. While this system is effective at producing data for cells in a three-dimensional structure, 
there are certain drawbacks. HCS screening produces very detailed, semi-accurate data, but the 
HCS process takes a very long time to produce data. In clinical applications, to produce results 
for a device, this method would not be effective because of this long wait time between trials.  
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           Biowire technology attempts to mimic cardiac tissue by providing a three-dimensional 
scaffold for cells to organize. This system uses pluripotent stem cell derived cardiomyocytes, 
which are assembled onto three-dimensional cardiac tissue (Nunes, et al., 2013). The fibers are 
then distributed into well plates and electrical stimulation is applied to the fibers to monitor 
contraction. Calcium is then applied and data is gathered to monitor how pharmaceutical 
products affect cell properties. This system is very effective at gathering data on cell properties 
and their interactions with drugs; however, the mechanical strength of the Biowire is not 
adequate because the strands cannot handle proper electrical stimulation.  
2.5 Microthread System  
Cell-seeded biological sutures have shown great promise in the field of cell therapy. 
Researchers at Worcester Polytechnic Institute (WPI) have demonstrated that human 
mesenchymal stem cells (hMSCs) can be easily seeded on fibrin microthread sutures for efficient 
delivery to areas of cardiac infarction. Cells delivered by this method have been shown to 
differentiate into new cardiac cells and organize into properly functioning tissue constructs that 
contribute towards heart activity, thus restoring function lost by infarction (Singer, 2010). 
Fibrin microthreads are formed through the combination of fibrinogen and thrombin in 
narrow polyethylene channels. This fibrinogen-thrombin blend is extruded slowly into a HEPES 
bath and then dried, forming individual microthreads. These threads are then combined and 
twisted together in batches of four to twenty-four, called a fibrin bundle. These bundles are 
threaded through a surgical needle and folded over, forming the suture used in surgeries. Sutures 
and bundles are typically seeded with hMSCs prior to surgery using a rotator at low rpm to 
ensure consistent seeding. For detailed microthread extrusion and seeding procedures, see 
Appendix A (Cornwell et. al, 2011). 
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Fibrin microthreads are typically cut into 4 cm lengths and have diameters ranging from 
55 to 65 microns for individual threads. The ultimate tensile strength of a hydrated thread is 
roughly 4.5 MPa at a 50% strain rate, and crosslinking through UV light exposure doubles this 
figure and greatly increases thread stiffness. However, this exposure negatively impacts 
fibroblast proliferation on threads (Cornwell and Pins, 2007). 
Cornwell and Pins characterized the cell-seeding capacity of UV cross-linked and non-
UV crosslinked microthreads. In their study, bundles of ten fibrin microthreads were glued to 
glass coverslips. Bundles were then submerged in media (500,000 cells/mL), and attachment was 
measured through a live/dead assay. Qualitative results show that while initial seeding was 
similar between the two microthread test groups, after seven days proliferation of non-UV 
crosslinked threads was much higher (Cornwell and Pins, 2010). Similar quantitative seeding 
experiments on microthreads achieved seeding densities as high as 731  101 cells per mm2 and 
5,903  1,966 hMSCs per centimeter of suture length (Proulx et al., 2011)(Guyette et al., 2013). 
Fibrin microthreads have also been successfully loaded with fibroblast growth factor-2 (FGF-2) 
at concentrations up to 200ng/mL. While FGF-2 did not increase initial fibroblast attachment, it 
greatly boosted cell outgrowth and proliferation (Cornwell and Pins, 2010). 
Cells seeded on fibrin bundles support fibroblast attachment, proliferation, and alignment 
along the thread axis (Cornwell and Pins, 2007). These microthreads have been used to 
successfully treat large-scale musculoskeletal wounds in mice, reducing fibroplasia-associated 
collagen deposition while promoting formation of skeletal muscle fibers, connective tissue, and 
PAX7-positive cells (Domkinko et al., 2011). hMSCs can be easily seeded onto fibrin 
microthreads, enhancing efficiency and localization of cell delivery to specific regions of the 
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beating heart. This efficiency (63.6  10.6%) is much greater than injection of cells (11.8  
6.2%) (Guyette et al., 2013). 
In short, fibrin microthreads have demonstrated an impressive ability to deliver seeded 
cells to areas of cardiac infarction and help restore function in the area. This ability is primarily 
attributed to these bundles’ high cell seeding capacity and ability to organize these cells into 
functional tissue constructs that contribute to in vivo heart activity. It is likely that these attributes 
of fibrin microthreads can be applied to drug screening efforts and serve as a model system of in 
vivo cardiac activity. 
2.6 hMSCs and Neonatal Rat Cardiomyocytes 
Adult human mesenchymal stem cells (hMSCs) are self-renewing, multipotent precursor 
cells that can be isolated from a variety of locations in the body, most commonly the bone 
marrow stroma where stages of hematopoiesis are regulated. hMSCs can be grown in vitro to 
generate mesenchymal stromal cell cultures, which under certain conditions can differentiate into 
several cell types including myocytes (muscle cells), adipocytes (fat cells), chondrocytes 
(cartilage cells), and osteoblasts (bone cells) (Pittenger and Martin, 2004). Due to their 
differentiation capability, expansibility, and ease of isolation, the use of hMSCs as a tool for 
cellular therapy, tissue engineering, and regenerative medicine has been extensively studied for 
both research and clinical applications. Systemic infusion of hMSCs has proven to be beneficial 
in several pre-clinical models of tissue injury, including that of myocardial infarction. Since they 
easily proliferate, are easy to acquire, and maintain in the laboratory, hMSC cultures are 
advantageous to use in in vitro studies (Nombela-Arrieta, et. al., 2011). For example, they may 
be used in staining assays to give insight into cell density and viability achieved on scaffolds 
such as fibrin microthreads. 
17 
 
While hMSCs are a beneficial cell population to use for general cell viability and 
proliferation assays, they are not able to effectively serve as a cardiac model in vitro in their 
undifferentiated form because of their lack of cardiomyocyte-like properties, such as the ability 
to contract. Neonatal rat cardiomyocytes on the other hand provide an effective model for 
cardiac tissue, allowing for the study of morphological, biochemical, and electrophysiological 
characteristics of heart cells. The phenotype of neonatal rat cardiomyocytes is very stable, and, 
unlike adult cardiomyocytes, their contractile properties are similar to that of native heart tissue 
(Chlopčíková, et. al., 2001). Neonatal rat cardiomyocytes are able to spontaneously contract in 
vitro and are also able to be paced with the application of an electrical signal to achieve 
simultaneous contraction, mimicking the heart in vivo. However, these cells are not as readily 
available as hMSCs and are also extremely expensive so they are not an ideal cell choice for 
experiments not specifically related to assessing cardiac function. 
2.7 Stimulation of Cardiac Cell-Seeded Fibers 
One of the most important aspects of cardiac cell testing in vitro is the application of 
electrical stimulation. After creating a biological scaffold seeded with cardiomyocytes, it is 
necessary to pace the cells so that the structure may contract as one unit and behave 
mechanically as the heart does in vivo. Electrical stimulation of the cell-seeded scaffold may 
promote the cells to beat synchronously as well as increase the rate of cell contraction. 
Moreover, clinical trials suggest that longer duration of stimulation results in structures with 
greater tissue-like properties (Radisic, et al., 2004). Electrical stimulation may be achieved with 
a voltage generator or stimulator (a commonly used brand of stimulator is the Grass stimulator). 
Electrodes are placed on either side of the cell-seeded scaffold to send a current across the 
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structure to allow for simultaneous contraction, where the voltage may be altered using the 
electrodes, to gain the desired rate of contraction.  
In addition to electrical stimulation, the application of biological compounds can alter the 
rate of cellular contraction. For example, intracellular calcium within the heart is responsible for 
contractile force (Eisner, et. al., 2000). Calcium is released from the sarcoplasmic reticulum of 
cardiac cells during contraction to cause the cardiomyocytes___and thus the whole heart___to 
relax, a process known as excitation-contraction coupling. Introducing calcium to cardiac 
myocytes in culture or on a scaffold alters the cells’ contractile rate. Acetylcholine, a 
neurotransmitter, increases the outward movement of potassium ions in heart tissue, which 
increases the organ’s resting potential to decrease contractile force (Reinking, 2002). In clinical 
applications, acetylcholine is injected to decrease heart rate. It can be observed that calcium and 
acetylcholine can serve as positive and negative controls to test the reliability of a device that 
screens for adverse effects of pharmaceutical agents on cardiac function. 
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Chapter 3: Project Strategy 
To begin, we were provided with the following initial client statement from our advisor 
and client, Professor Glenn Gaudette: 
Design a device/system to incubate cells on fibrin microthreads to produce a 
muscle fiber that can be used for high throughput screening. The device/system 
should be easy to use (including loading cells, recording data, feeding cells, etc.), 
provide a sterile environment and fit in a standard cell incubator. The design 
should also allow for the reproducible loading of cells on the microthreads. The 
device/system should hold at least six cardiac muscle fibers. 
 
With information provided by Professor Gaudette and our background research, we took 
this initial client statement and developed a thorough list of objectives. From this list, we 
distinguished between primary and secondary objectives and then ranked our primary objectives 
using a pairwise comparison chart as seen in Appendix B.  
The following is our final ranked list of primary objectives, with secondary objectives 
listed underneath: 
1.  Reliable 
a.    Reproducible 
b.   Accurate 
2.  Biocompatible 
a.    Optimize cell growth 
b.   Prevent byproducts 
c.    Minimize contamination 
d.   Easily sterilizable 
3.  Easy to use 
a.    Easy to acquire data 
b.   Seed cells 
c.    Change media 
d.   Add/remove microthreads 
e.   Add/remove pharmaceutical agents 
4.  Safe for user 
5.  Cost-effective 
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Our pairwise comparison analysis ranks reliability as the most important aspect of our 
design. A major drawback of current screening methods is their use of two-dimensional cellular 
systems to model cardiac tissue. Our screening device relies on three-dimensional fibrin 
microthread scaffolds to better depict the structure of natural heart tissue. Therefore, we focused 
on developing a screening device that can acquire data quickly and reliably.  Device 
biocompatibility and ease of use are important in providing accurate data with minimal effort 
required from the operator. Safety, while important as a constraint, is not as vital as device users 
will be experienced and highly trained in laboratory safety. Cost effectiveness plays a minor role 
in our design, as a more expensive but higher quality device would be preferred. 
The most and least important objectives were assigned unanimously among all group 
members. There was slight debate when ranking the importance of biocompatibility, ease of use, 
and safety, though these discrepancies were resolved through majority voting and collaboration 
with our advisor. 
Along with these identified and ranked objectives, we also determined several design 
constraints for our device: 
1.  Fit in a standard cell incubator 
2.  Allow for gas exchange 
3.  Zero contamination 
4.  Sterilizable 
5.  House 6+ fibers 
With these objectives and functions, and through feedback from Professor Gaudette, we 
revised our initial client statement as follows: 
Design a device to incubate cardiac myocytes and/or stem cells on fibrin 
microthreads to produce “muscle fibers” that contract upon stimulation. The 
device should collect contractile data and allow for high throughput screening 
(HTS), defined as twelve fibers per hour. It should hold at least six cardiac muscle 
fibers at a time and allow for the addition and removal of various pharmaceutical 
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agents. It should be easy to use, provide a sterile environment, and fit in a 
standard cell incubator. The design should allow for the reproducible loading of 
cells on microthreads. 
 
3.1 Technical Approach 
 With this revised client statement, we were able to develop our project approach. We first 
worked with fibrin microthreads produced by Vitathreads to establish hands-on knowledge of 
their mechanical properties. In addition to handling the threads, we performed extensive 
background research on their mechanical properties. This allowed us to better understand the 
physical properties of these microthreads and identify ways in which these threads can be used in 
future device designs. 
 We explored and practiced cell culture techniques necessary for growing and maintaining 
healthy hMSCs and rat cardiomyocytes, including feeding and passaging. This prepared us for 
future tests involving cell seeding and testing. 
 With a strong understanding of the properties of microthreads and the cells being seeded, 
we then developed several design alternatives. All designs were compared using a numerical 
evaluation matrix, and the top scoring designs were considered. We established mathematical 
models and performed theoretical calculations to ensure that our selected design was feasible 
before proceeding to revise and develop the design. 
 Once our final preliminary design was optimized, we drafted a Solidworks model to 
better visualize the design’s components and plan how to best building the prototype. This model 
was further revised to emphasize our objectives. We then ordered the necessary materials and 
constructed the prototype. This prototype was tested to validate whether or not the design met 
our objectives and constraints. 
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3.2 Management Approach 
 To ensure we made constant progress throughout the year, we held weekly meetings with 
our client and advisor, Professor Glenn Gaudette. These meetings were used to update Professor 
Gaudette on our progress, review our work during the previous week, and set long and short-
term goals for future weeks. In addition to these meetings, we developed a work breakdown 
structure (Appendix C). To accomplish our overall goal of designing a device for the evaluation 
of contraction on cell-seeded fibers, we developed eight different requirements. These included 
understanding client requirements, analyzing functional requirements, generation of design 
alternatives, evaluation of alternatives, selection of the best alternative, construction of a 
prototype, documentation of the process, and project management. The timeline to perform each 
of these tasks is included as a part of our quarterly Gantt charts (Appendix D). Following these 
tasks and set timeline ensured that we were able to successfully complete our project 
requirements in a timely manner. 
3.3 Financial Approach 
 Material costs were the main source of spending. Our device was anticipated to require 
media, materials to hold the thread and media, fibrin bundles, and cells to seed onto bundles. 
Media came included in the $100 cost to use equipment in the Goddard Lab. Fibrin bundles were 
provided to us by Vitathreads free of charge, and the Gaudette lab provided us with cells to use. 
We had our remaining budget available to spend on materials to make our device. The materials 
came at a low cost, far below our allotted budget. There was no cost associated for the labor 
required for producing our device prototype, as assistance was provided by the Higgins Labs 
Machine Shop free of charge. We expected the cost of materials and manufacturing of our 
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prototype to be far below our allowed budget, allowing for flexibility in the future for any 
necessary changes to our final design.  
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Chapter 4: Alternative Designs 
Upon establishing our project strategy, the team proceeded to develop preliminary device 
designs, evaluate these designs, and select the design that best achieved the goals of the project. 
4.1 Needs Analysis 
 Given our list of objectives identified in Chapter 3, we assigned weights to help quantify 
the relative importance of each objective. We decided to use a 1-10 scale, with one being a less 
important objective and ten being very important. These scores are displayed in Table 4.1.  
Table 4.1: Weighted Objectives Table 
Objective Score 
Reliable 10 
Biocompatible 9 
Ease of Use 7 
Safe for User 4 
Cost-effective 2 
  
 We previously identified reliability and biocompatibility as our most important 
objectives. Thus, we decided to set these objectives as the upper limit of our ten-point scale. 
Because we value reliable measurements above biocompatibility, we gave biocompatibility a 
slightly lower weight of nine. We proceeded to weight the remaining three objectives based on 
their relative importance to reliability. Ease of use is a fairly important objective that will be a 
key focus of our device development. An easier, simpler device is more appealing from a buyer 
and operator standpoint, and so we gave this objective an above average weight. The last two 
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objectives were not as critical to the design of the project and thus received below average 
scores. 
 By using a broader ten-point scale versus a typical linear scale, we are able to better 
specify the importance of each objective for a more accurate final evaluation of conceptual 
designs. 
4.2 Functions and Specifications 
 Through discussions with our client and group research, we identified the following 
design functions and specifications corresponding to these functions, shown in Table 4.2. 
Table 4.2: Functions and Specifications 
Functions Specifications 
 
Facilitate seeding, growth, and contraction of 
hMSCs and rat cardiomyocytes 
 
Seeding density must be comparable to 
731 cells/mm2 (2,296 cells/cm) 
Contractile force comparable to theoretical 
calculation of 5.442 µN for a 1 cm thread 
Electrically stimulate the cells to cause 
contraction 
Provide voltages between (0 and 1V/cm) 
 
Allow for addition/removal of threads, media, 
and pharmaceutical agents 
Media volume must sustain cell health for 
two-three days before changing 
Hold threads and media Well size – accommodate threads 1 – 4 cm 
in length 
Collect quantitative data for contraction rate and 
force 
Screen a minimum of 12 fibers per hour 
 
Allow for incubation of cells Size smaller than 17”x20”x20” 
 
First and foremost, our device must facilitate the seeding and growth of human 
mesenchymal stem cells as well as the seeding, growth, and contraction of neonatal rat 
cardiomyocytes on fibrin microthreads. Previous research on fibrin microthreads has shown 
seeding densities of 731 cells per square centimeter (Proulx, et al., 2011). Our device should 
yield seeding densities similar to or better than this to be considered successful. Based on this 
cell density, a typical microthread with a diameter of 0.1 mm will have enough cells to produce a 
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contractile force of 5.441 µN per centimeter of thread length (see calculations in Design 
Calculations). Threads housed in our device should achieve contractile forces comparable to this 
calculation. 
 Electrical stimulation enables the user to control the contraction rate of the microthread. 
Past research suggests that the maximum voltage necessary to fully stimulate hMSCs is 1 volt 
per centimeter (Sun, et al., 2007). Thus, our device should allow for the application of zero to 
one volts of electricity to each thread. 
 Our device must be able to house microthreads of varying lengths and keep them 
hydrated in media. Typical microthreads used in surgical applications vary between one and four 
centimeters in length, and therefore the compartment containing the thread must accommodate 
these thread sizes (Guyette, et al., 2013). Our design must also be tailored towards easy addition 
and removal of threads, media, and various pharmaceutical agents. The volume of media being 
added and removed depends on the well size. We need to ensure that the wells contain enough 
media to keep seeded cells healthy for at least two days at a time to reduce work required by the 
operator. However, minimizing the volume of media helps to save money and time required to 
prepare the media. 
To promote a high throughput aspect of our device, we have established that our device 
must collect and interpret quantitative data for the contractions of twelve threads per hour. This 
is related to a second specification that our device holds at least six threads at a time. Our device 
must also fit in a standard cell incubator, measured to be 43x51x51 cm. This is the absolute size 
restriction. However, many incubators have removable shelves with adjustable heights. To allow 
for the sharing of incubator space with our device, we would prefer to minimize the height as 
much as possible. 
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4.3 Conceptual and Preliminary Designs 
 
We established six conceptual designs that performed our functions and met our 
specifications outlined in the previous section. Each design incorporated different thread holding 
mechanisms and data collection methods. Sketches, descriptions, advantages and limitations of 
each of these designs are provided in the following sections. 
4.3.1 Wheel and Camera 
 
 
Figure 4.1: Wheel and Camera Sketch 
The wheel and camera design uses an interchangeable rotating disk coupled with a 
handheld microscope for imaging and data collection (Figure 4.1). Cell-seeded microthreads are 
placed in media-containing wells arranged around the center of the disk. Threads are held in 
place at both ends by two small slits built into the wells. As various chemical agents are 
introduced into each well, a handheld microscope, held in place by a stand, records video of the 
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contraction of each thread. This video is displayed on a nearby computer in real time. The entire 
disk is rotated to image each of the wells while keeping the microscope stationary. 
This design is very high-throughput. Each one of the interchangeable disks holds several 
threads at a time, allowing for the data collection of many threads. With interchangeable disks, 
one set of threads can be imaged or tested while another set undergoes seeding or growth. A 
stationary camera eliminates the need to readjust and refocus the camera between threads, 
making it easier for an operator to use. The well design promotes cell viability and thread 
integrity by allowing for minimal thread handling; the user loads the threads into the device a 
single time and never has to touch them again. However, this design may be limited by its 
inability to acquire quantitative contractile force data. 
4.3.2 Spring and Camera 
 
 
Figure 4.2: Spring and Camera Sketch 
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The spring and camera design, shown in Figure 4.2, uses a rectangular plate with six 
long, narrow wells in which the microthreads are held. In each well, the two ends of the 
microthread are clamped, and the thread is stretched taut and looped around a hook attached to a 
sensitive spring on the opposite end. A micro-scale ruler is etched beneath the spring, and a 
stationary handheld microscope video records the oscillations of the spring relative to this ruler, 
displayed on a computer monitor. With a known spring constant and a measured displacement, 
quantitative contractile force can be calculated through the equation F = kx, where k is the spring 
constant and x is displacement of the spring. This design is limited by the ability to purchase a 
spring sensitive enough to oscillate under lower forces provided by a cell-seeded microthread. In 
addition, it is difficult to measure data accurately, because the small-scale microruler may be 
difficult to read. 
4.3.3 Limit Switch 
 
 
Figure 4.3: Limit Switch Sketch 
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The limit switch design uses a six-well plate with rectangular wells inside which 
microthreads are held in media (Figure 4.3). The two ends of the fiber are clamped at one end of 
the well and the thread is stretched taut and looped around the arm of a limit switch. As various 
chemical agents are introduced into each well, the limit switch is repeatedly tripped in response 
to the contractions of the thread. The limit switch is hooked up to a computer that displays an 
on/off output to determine whether the fiber is contracting or not. The binary nature of the data 
collected through this method is very easy to interpret. However, a limit switch design cannot 
calculate important multi-faceted contractile data such as force or rate. It is also possible that the 
limit switch will not have a high enough sensitivity to be triggered by a contracting microthread. 
In addition, a significant amount of thread handling is required to load each thread, which could 
potentially affect thread integrity. 
4.3.4 Oscillating Weight and Transducer 
 
 
Figure 1.4: Oscillating Weight Sketch 
31 
 
The oscillating weight design, shown in Figure 4.4, incorporates a tall, cylindrical 
reservoir of media with a removable cover onto which a hook is attached. A small-scale weight 
is attached to the two ends of a microthread, and the thread is then looped onto the hook. The 
cover, with the thread attached, is lowered into the reservoir. As the fiber contracts, it will pull 
the weight upwards. Gravity will then lower the weight back to the original location. An 
ultrasound transducer, coupled with a piezoelectric crystal at the bottom of the tube, detects this 
oscillating weight through changes in the time interval of signals being transmitted and reflected 
off of the weight. The change in time interval can be used to calculate the force of contraction. 
The transducer is hooked up to a computer, which displays a software-generated graph of 
distance versus time to determine the rate and relative force of contraction. This design allows 
for easy interpretation of data, as it provides concrete quantitative distance values over time. 
Ultrasound transducers also have the sensitivity required to detect the small contractile 
movements of microthreads, which is a distinct advantage over many other designs. However, 
this design is not particularly user friendly. It requires long preparation time, because it can be 
difficult to attach the weight onto the thread and line it up with the transducer on a consistent 
basis. 
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4.3.5 Cantilever Beam and Transducer 
 
 
Figure 4.5: Cantilever Beam Sketch 
This design uses a six-well plate with rectangular wells, inside which microthreads are 
held in media (Figure 4.5). The two ends of each thread are clamped at one side of the well, and 
the thread is stretched taut and looped around a sensitive cantilever beam. The beam deflects in 
response to the contraction of the thread. An external ultrasound transducer determines the 
displacement of the post, and this value can be used to calculate the force of contraction. A 
computer displays a software-generated graph of deflection versus time to determine the rate and 
relative force of contraction. This design allows for easy interpretation of data, as it provides 
concrete quantitative distance values over time. The ultrasonic transducer is sensitive enough to 
detect the small deflections of the cantilever beam. However, the design may not be easily 
reproducible, because all threads need to be anchored at the same height on the post for each test 
to ensure accurate measurements. There is also a high level of thread manipulation required. 
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4.3.6 Force Transducer and Spring 
 
 
Figure 4.6: Force Transducer Sketch 
This design uses a six-well plate with rectangular wells inside which threads are held in 
media (Figure 4.6). The two ends of each thread are clamped on one side of the well, and the 
thread is stretched taut and looped around a spring attached to a mechanical force transducer. 
The transducer will measure the force generated by the thread and send this data to a computer, 
which displays a force versus time graph. This design directly measures quantitative force data 
over time, and thus no calculations or data interpretation is required. However, finding a force 
transducer sensitive enough to detect micro/nano-scale forces may be difficult. 
4.4 Design Evaluation Matrix 
To determine how well each of our conceptual designs met our objectives, we evaluated 
each design using the weighted objectives table developed in section 4.1. The results are shown 
in Table 4.3. 
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Table 4.3: Design Evaluation Matrix 
Objective 
& Weight 
Wheel & 
Camera 
Spring & 
Camera 
Limit 
Switch 
Weight & 
Transducer 
Cantilever 
Beam & 
Transducer 
Force 
Transducer 
& Spring 
HTS   
(10) 
8 4 5 3 6 4 
Biocomp. 
(9) 
9 5 5 3 7 4 
Easy to 
Use (7) 
8 6 7 4 6 5 
Safe for 
User (4) 
9 8 7 7 8 7 
Cost-
Effective 
(2) 
7 3 4 4 6 4 
       
Total 41 26 28 21 33 24 
Weighted 
Total 
267 165 180 121 209 147 
 
We assigned a score between one and ten for how well we perceived each design to meet 
each objective. We then tabulated two scores for each design: raw and weighted. Raw scores 
were calculated by adding the five scores obtained from each objective. The weighted scores 
took each score and multiplied it by the relative importance of the objective (shown in 
parentheses). These weights were established in Chapter 3.  
As determined by our evaluation matrix, the rotating disk design received both the 
highest raw total and highest weighted total, suggesting that overall, this design best achieves our 
objectives. Our cantilever beam and transducer design received the second highest scores. There 
were aspects of this design that we felt were very strong, particularly its ability to provide 
quantitative data that cannot be obtained through using just a camera. Thus, our team decided 
that it was best to incorporate aspects from both of these designs when establishing a preliminary 
design. By using a combination of a camera and cantilever beam, our device can collect both 
qualitative and quantitative contractile information. 
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4.5 Design Calculations 
We assessed the feasibility of our cantilever beam/camera hybrid design through 
mathematical models to calculate theoretical cantilever beam deflections. We used the following 
model, shown in Figure 4.7 below.  
 
Figure 4.7: Cantilever Beam Model 
We found that a single cardiomyocyte can produce a force of 2.37 nN (Nishimura, 2004). 
We used this figure along with previously mentioned data for the cell-seeding of microthreads to 
perform the following calculations that estimate the contractile force generated by a 1cm long 
fibrin bundle, where L is the length of the thread, D is the diameter, C is the circumference, and 
SA is the surface area. 
FORCE PER CENTIMETER OF THREAD 
 
L = 1 cm = 10 mm 
D = 100 micrometers = 0.1 mm 
C = pi*D = 0.31416 mm 
SA = C*L = 3.1416 mm^2 
Cell density * SA = 731 * 3.1416 = 2296 cells/cm 
2296*2.37nN = 5,442 nN = 5.442 µN 
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These calculations suggest that a contracting fibrin bundle seeded with a few thousands 
cells should produce forces on the scale of micronewtons. Therefore, we need a cantilever beam 
and camera setup that can detect forces on the micro-scale. Using a standard cantilever beam 
equation (Equation 4.1) along with previously identified dimensions of our cantilever beam, we 
can solve for a desired range of elastic modulus for our cantilever beam material. Alternatively, 
if a material has been selected, we can use its elastic modulus to solve for its optimal dimensions. 
Equation 4.1: Deflection equation for end-loaded cantilever beams 
 
In equation 4.1, P is the force on the end of the beam, L is the length of the beam, E is the elastic 
modulus, and I is the moment of inertia of the beam’s face. We generate an excel sheet of 
deflection values for two cantilever beam materials in Chapter 5, Section 1. 
4.6 Preliminary Designs 
 Once our team decided on a camera-cantilever beam device, we worked towards 
developing several preliminary designs that incorporated these features. Considerations for 
design included cantilever beam orientation (standard or inverted), beam design, notch design, 
well size and number, well arrangement, and camera orientation. The following sections discuss 
alternative approaches to each of these aspects and explain our reasoning for selecting each 
feature for use in our final design. 
4.6.1 Cantilever Orientation 
 The team considered three potential mounting orientations for the cantilever beams: 
upwards, downwards, and sideways. These orientations are illustrated in Figure 4.8. With the 
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cantilever beam mounted sideways, gravity becomes a potential problem. A long, narrow, 
flexible post may sag under its own weight and thus skew our measurements. Additionally, 
mounting beams to the side of each well is a more difficult process than is required of the other 
orientations. While the upwards and downwards posts can stand or hang respectively, a sideways 
post requires adhesives or overly complex anchoring mechanisms. 
 
Figure 4.8: Cantilever Beam Orientations 
 There are several advantages to a downward-oriented cantilever beam system. To 
maximize cantilever displacement due to thread contraction, it is important to anchor the thread 
as close to the end of the cantilever as possible. In the upwards model, the thread is anchored 
towards the top of the well. This leads to reduced protection of the thread and an increase in 
media required (the entire well must be filled to keep the thread hydrated). The downwards 
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model solves these problems by encouraging the thread to be anchored towards the bottom of the 
well, increasing protection offered by the well and reducing the media requirement. Furthermore, 
with the upwards model, the cantilever beams are fixed to the well base. This restricts the user to 
loading each thread inside the small well volume. Loading by hand will be very difficult and 
require the assistance of tools. Attaching the cantilever beam to the lid in the downward model 
allows the user to remove the beam from the well and load the thread in free space. Based on the 
advantages provided by the downward orientation of cantilever beams, we have decided to use 
this feature in our final design. 
4.6.2 Cantilever Beam and Notch Design 
 We considered both PDMS and 304 stainless steel wire as our cantilever beam material. 
PDMS is readily available in most labs, highly biocompatible, and has a low elastic modulus. 
However, producing these posts takes about a day and may be difficult due to the small diameter 
required. Stainless steel is also biocompatible and comes in dimensions as small as 0.005 inches. 
There is no production time associated with a stainless steel cantilever beam, however stainless 
steel is much stiffer than PDMS and may not deflect as much. 
 The user must be able to anchor seeded microthreads to our cantilever beams. PDMS is 
very rubbery, and a notch can be cut to serve as an anchor point for the microthread. We 
considered several notch designs that facilitated the reproducible attachment of threads on PDMS 
cantilever beams. The profiles of each notch are shown in Figure 4.9. 
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Figure 4.9: Notch Profiles 
 There were three basic designs: a centered notch, edge-justified notch, and a side notch. 
While all three designs are feasible with an upwards-oriented cantilever beam, only design three 
is compatible with our downwards-oriented system. This is because notches one and two risk 
thread slippage or detachment due to gravity. 
 A notch cannot be carved into a stainless steel cantilever beam. Instead, to anchor the 
microthread, a bend can be applied to the end of the beam that will prevent slipping of the thread 
(Figure 4.10). 
 
Figure 4.10: Stainless Steel Post Profiles 
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4.6.3 Well Size & Number 
 When determining the size of each well, it is important to consider the desired length of 
threads to be tested. Based on our research, microthread sutures used for surgery typically range 
from one to four centimeters in length, with two centimeters being most common. For the 
greatest flexibility, our wells should accommodate for the testing of four centimeter-long threads. 
Since our device requires the user to wrap the thread around the cantilever beam and clamp it at 
the other end, the final length of the thread will be half of its original length. Therefore, the 
distance between our anchor points should be around two centimeters long. Wells must be wide 
enough to accommodate this length. 
Regarding well number, our client requests that our device hold a minimum of six wells 
(see Revised Client Statement in Chapter 3). For design simplicity, we have decided that our 
device will have six wells. Our design can be scaled up to incorporate more wells in the future if 
necessary. 
4.6.4 Camera Orientation 
 We have established that our device will use a camera/microscope in conjunction with 
flexible cantilever beams to image and determine the contractile strength of cell-seeded 
microthreads. There are four possible ways to orient the camera for imaging: top, bottom, 
sideways, and angled. These orientations are illustrated in Figure 4.11. 
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Figure 4.11: Potential Camera Orientations 
An angled orientation (number 4) complicates the deflection measurements of the posts 
by distorting the image seen by the camera. Therefore, we ruled out having the camera at an 
angle. With a downwards-oriented cantilever beam system, a top-down camera (number 1) is not 
feasible. The camera would be too far away from the point of deflection and its view would be 
obstructed by components on the lid. Both the bottom-up and sideways camera orientations are 
valid options, and thus we considered well plate designs that incorporated the ability to be 
measure by either method. 
4.6.5 Well Arrangement 
The arrangement and orientation of the six wells is an important aspect that has a major 
impact on our design’s final appearance. We considered three potential arrangements that 
minimized our device’s footprint (Figure 4.12). We acknowledge the benefits of having a 
stationary camera during imaging. A stationary camera allows for more reproducible 
measurements, because the camera images the exact same location every time. It is also easier 
42 
 
for the user, as a stationary camera reduces the need to readjust and refocus the camera between 
wells. Therefore, we developed these well orientations with a stationary camera in mind.  
 
Figure 4.12: Possible Well Orientations 
Designs 1 and 2 are more traditional rectangular arrangements. These designs are likely 
easier to manufacture, and well plates featuring these arrangements are very common. The one-
by-six arrangement allows for a single camera to image all wells without needing to move. This 
can be accomplished by sliding the well plate along a track parallel to its long axis, past the 
imaging camera. However, a one-by-six arrangement creates a very long dimension that can be a 
burden in the lab. The two-by-three design has friendlier dimensions, but requires a more 
complex mechanism to image all of the wells with a single, stationary camera. Design 3 arranges 
the wells in a circular pattern that can be rotated around a stationary camera either in the center 
of the well plate or on the periphery. However, this design uses space inefficiently compared to 
the rectangular arrangements and is more complex to manufacture. 
After discussion, our group decided on a two-by-three well plate, because its dimensions 
are the most versatile and plates like these are common and easily purchased. 
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4.6.6 Summary 
A summary of our preliminary design analysis is shown in the table below. 
Table 4.4: Summary of Results 
Feature Result 
Beam Orientation Downwards 
Beam Material PDMS or SS 
Notch Design Side Notch or Bend 
Well Size and Number ~2cm, Six Wells 
Camera Orientation Sideways, Bottom-up 
Well Arrangement 2x3 Rectangle 
4.7 Final Design 
 Our team first considered a reusable well plate design made out of polycarbonate. 
Polycarbonate is a transparent polymer that can withstand temperatures and pressures of an 
autoclave, making it sterilizable between uses and a good candidate for a reusable plate material. 
Unfortunately, the polycarbonate slabs needed to machine our well plate were too expensive to 
consider further. We tried designs in which just the bottom panel, the one through which the 
microscope images, is polycarbonate. However, this lead to unwanted complex design 
components. 
 We instead opted to integrate a preexisting disposable well plate into our design. We 
designed a reusable polycarbonate insert that is compatible with six-well plates from companies 
including Celltreat, Falcon, and Corning. This allowed us to maintain device reusability while 
minimizing manufacturing costs. Using a standard six well plate adheres to all of the design 
considerations discussed in the previous section. Wells are arranged in a 2x3 rectangle and have 
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a diameter of 3 cm and depth of 2 cm. They allow for imaging from the bottom and enable a 
downwards cantilever beam orientation. A typical six-well plate is shown in the figure below. 
 
Figure 4.13: Standard Six-Well Plate 
 Figure 4.14 is a Solidworks model of our insert. Twelve rectangular holes are drilled into 
a thin (1/16”) polycarbonate sheet. These holes accommodate removable PDMS anchor points 
illustrated in Figure 4.15. The insert is dimensioned and cut to fit into a standard six-well plate. 
 
Figure 4.14: Polycarbonate plate insert 
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Figure 4.15:  Full assembly of plate insert 
First, the PDMS anchor points (shown in blue in Figure 4.15) are created by following 
the protocol in Appendix E. These anchor points are then gently pushed into the holes of the 
insert. PDMS or 304 stainless steel cantilever beams (shown in red in Figure 4.15) are prepared 
as described in the protocol in Appendix E and inserted into the plate adjacent to the anchor 
points. Using a razor blade, a slit is cut down the middle of the anchor point. A seeded 
microthread is wrapped around the cantilever beam, and the free ends of the thread are pinched 
inside the slit in the anchor point. This process is repeated five times, and the entire insert is 
transferred to a six-well plate containing fresh media. The entire assembly, including the plate, 
the insert, and the removable anchor points, is shown in Figure 4.15. The detailed protocol can 
be found in Appendix E. The fully assembled plate can be imaged under a microscope to record 
contractile data. 
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Chapter 5: Design Verifications 
 Our team conducted a series of tests to verify that our device satisfied our objectives. Our 
device had to be used effectively and collect results properly and reliably. These tests allowed 
the team to identify the effective elements of our design and the areas of improvement required 
in the future. 
5.1 Mathematical Model Calculations 
 Before any testing occurred, we took the mathematical model developed in Chapter 4 and 
produced an excel sheet (Table 5.1) of theoretical deflection values of PDMS cantilever beams. 
Table 5.1: PDMS cantilever beam deflection calculations 
 
Based on these calculations, a cylindrical PDMS cantilever beam with a diameter 0.5-2.5 
mm and length of 10-30 mm will deflect a distance on the order of millimeters to microns. With 
the assistance of magnification from a microscope objective, this deflection should be easily 
detectable, suggesting that PDMS is a good cantilever beam material. 
Length of Beam (mm) Load (N) Young's Modulus for SS(MPa) Radius (mm) moment of inertia (mm^4) Displacement (mm) Displacement (microns)
10 5.44E-06 0.36 0.5 0.049 0.103 102.651
15 5.44E-06 0.36 0.5 0.049 0.346 346.448
20 5.44E-06 0.36 0.5 0.049 0.821 821.211
25 5.44E-06 0.36 0.5 0.049 1.604 1603.928
30 5.44E-06 0.36 0.5 0.049 2.772 2771.588
10 5.44E-06 0.36 1 0.785 0.006 6.416
15 5.44E-06 0.36 1 0.785 0.022 21.653
20 5.44E-06 0.36 1 0.785 0.051 51.326
25 5.44E-06 0.36 1 0.785 0.100 100.246
30 5.44E-06 0.36 1 0.785 0.173 173.224
10 5.44E-06 0.36 1.5 3.976 0.001 1.267
15 5.44E-06 0.36 1.5 3.976 0.004 4.277
20 5.44E-06 0.36 1.5 3.976 0.010 10.138
25 5.44E-06 0.36 1.5 3.976 0.020 19.802
30 5.44E-06 0.36 1.5 3.976 0.034 34.217
10 5.44E-06 0.36 2 12.566 0.000 0.401
15 5.44E-06 0.36 2 12.566 0.001 1.353
20 5.44E-06 0.36 2 12.566 0.003 3.208
25 5.44E-06 0.36 2 12.566 0.006 6.265
30 5.44E-06 0.36 2 12.566 0.011 10.827
10 5.44E-06 0.36 2.5 30.680 0.000 0.164
15 5.44E-06 0.36 2.5 30.680 0.001 0.554
20 5.44E-06 0.36 2.5 30.680 0.001 1.314
25 5.44E-06 0.36 2.5 30.680 0.003 2.566
30 5.44E-06 0.36 2.5 30.680 0.004 4.435
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5.2 Imaging Capability 
 With the table of displacement values calculated in section 5.1, our cantilever beams would 
be displacing distances on the scale of millimeters. Thus, we needed an imaging system that could 
magnify this displacement to more easily distinguish between actual deflection and background 
movement. We designed our device to be used with a standard laboratory microscope. Since these 
microscopes can produce high quality images at magnifications ranging between 2X and 100X, 
these microscopes should greatly increase our device’s detection sensitivity. 
 To test a microscope’s ability to image fibrin bundles in our device, we loaded a bundle into 
our device, inserted our device into a six-well plate, and placed the assembly in a Zeiss PrimoVert  
 microscope. Representative images can be seen in Figures 5.1 and 5.2 below. 
 
Figure 5.1: 100X image of fibrin bundle loaded in device 
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Figure 5.2: 40X image of fibrin bundle around cantilever beam 
 Our device allows for extremely high quality images at magnifications as high as 100X. 
This means that the initial millimeter deflection produced by a contracting thread should appear as 
a centimeter deflection on camera. 
5.3 Microthread Loading and Fixation Testing 
 Once we identified PDMS as the material of choice for both the anchor point and 
cantilever beam, we conducted tests to quantify the anchor point’s ability to hold a fibrin bundle 
in place without slipping. Our anchoring mechanism relies on a pinching mechanism, where a 
slit is cut into a piece of PDMS and the thread is flossed into the slit. We conducted a gravity-
based testing rig to determine how much weight could be supported by this pinching of the fibrin 
bundle. Our polycarbonate plate insert was arranged perpendicular to the surface of tabletop, and 
both ends of a 12-thread fibrin bundle were loaded in the slit of a PDMS anchor point. A 
paperclip was hung on the loop created by the bundle, and weights of increasing mass were hung 
off the paperclip until the bundle slipped out of the anchor point. Figure 5.3 below illustrates the 
set-up of this experiment: 
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Figure 5.3: Diagram of Loads on PDMS Anchor Point Slit 
Figure 5.4 shows an actual picture of our experiment. We started with 5 grams of weight 
and waited 10 seconds before adding an additional five grams. We continued this until the slit 
failed and the weighted suture slipped, occuring at approximately 15 grams. Using gravity and 
the known mass, we calculated the force with the equation F=ma. Since slipping occurred 
between 10 and 15 grams of weight, we can say that our anchor point holds loads between 0.1 to 
0.15N. Since contracting microthreads were estimated to produce forces on the scale of 
micronewtons (see Chapter 4), no slipping should occur in our device due to the contraction of 
these threads. 
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Figure 5.4: Picture Taken From PDMS Anchor Point Loading Testing  
5.4 Sterilization Testing 
 To make sure that out device could be reused, we tested whether or not our polycarbonate 
insert and PDMS anchor points and cantilever beams could be sterilized. The Gaudette lab uses 
ethylene oxide gas to sterilize the materials they use for experiments involving microthreads. 
Therefore, we tested the ability of our device’s components to be sterilized by this method. 
Anchor points and cantilever beams were placed in an autoclave bag and gassed for twenty-four 
hours. We noticed slight expansion of the anchor points and cantilever beams after the gassing 
process, hindering the ease in which they could be inserted into the polycarbonate insert. This 
can be overcome by loading these features into the insert before the gassing process. The anchor 
points and cantilever beams are meant to be disposed after testing and do not require repeated 
sterilization. 
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  The polycarbonate insert was placed inside a separate autoclave bag and gassed also 
gassed for twenty-four hours. The polycarbonate insert showed no changes in properties after the 
gassing process, suggesting that this insert can be sterilized multiple times for reuse. 
Polycarbonate should also withstand the temperatures and pressures of an autoclave, though 
these tests have not been conducted. 
5.3 Cell Retention Testing 
 
We conducted a series of cell staining procedures to assess our device’s ability to 
maintain cell health and viability and qualify the presence of cells and seeding capacity of fibrin 
microthreads. Two fibrin microthreads were seeded with human mesenchymal stem cells 
following the seeding protocol in Appendix E. One thread was stained immediately upon 
completion of the seeding process with Phalloidin and Hoechst dyes (P/H protocol in Appendix 
E). The second thread was loaded in our device and incubated for three hours before being 
stained in the same way. Two representative Phalloidin/Hoechst staining images are shown side-
by-side in Figure 5.5. 
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Figure 5.5: Images Taken During Phalloidin/Hoechst Staining: 
Left Image: t = 0 thread (control); Right Image: t = 3 hours thread (experimental) 
 
The green channel is Phalloidin, which stains the cytoplasm of cells. Hoechst is the blue 
channel and stains for cell nuclei. These two images, t=0 and t=3, show very similar cell density 
and morphology, suggesting that cells are not lost or altered during the loading process of our 
device. 
 We followed up with a live/dead assay to assess the viability and health of these cells. 
We produced two additional hMSC-seeded fibrin bundles. We loaded one of these bundles into 
our device for three hours before staining, while the other bundle was stained immediately. 
During staining, threads were cut into thirds. One third was used as a dead control, where cells 
were purposely killed with 70% ethyl alcohol. The other two sections were used as our 
experimental groups. Sections were stained as described on the protocol in Appendix E. 
Additional images of the Phalloidin/Hoechst stains are found in Appendix F. 
 Figure 5.6 shows Live/Dead images of time point t=3. The experimental image is shown 
on the right, with the corresponding dead control on the left. 
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Figure 5.6: Images Taken During Live/Dead Staining (Live, Dead and Overlay Images): 
Left Images – Dead Control (control); Right Images – Thread at t = 3 hours In Device (experimental) 
 
The cytoplasm of living cells are stained in green by calcein AM, while the nuclei of 
dead cells are marked red by ethidium homodimer-1. The Hoechst stain (blue) indicates where 
cells are present in the image.  
Looking at the dead control on the left, there is no signal in the live channel. Meanwhile, 
there are many visible red dots in the dead (red) channel, indicating regions in which cells are 
dead. Looking at the overlay image on the bottom, these red dots line up with the Hoechst 
staining (shown by the white arrows), indicating that cells in our control are indeed dead. 
Our experimental group on the right shows the presence of live staining. There is also an 
absence of red dots in the dead channel. Based on the overlay image at the bottom, the live 
(green) staining lines up with the Hoechst staining, suggesting that these cells are alive. The rest 
of our staining images can be found in Appendix F. 
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5.5 Contraction and Imaging Testing 
 The overall goal of this project was to load cadiomyocyte-seeded fibrin microthreads into 
our device and record their contraction using a laboratory microscope. We obtained four fibrin 
microthreads that were seeded with neonatal rat cardiomyocytes. These threads were incubated 
in media for three days as the group monitored them for spontaneous contraction. Although there 
was no noticeable detection of spontaneous contraction, the team successfully loaded the threads 
into our device. The threads were difficult to load because the three-day incubation period 
significantly weakened the mechanical properties of the threads. One thread was loaded 
successfully, though no contraction could be observed under a microscope with or without 
electrical stimulation provided by a Grass stimulator.  This thread provided proof of principle 
that our threads could be loaded into our device. We were also able to obtain videos of the thread 
and the cantilever beam showing that we could acquire data if the threads were contracting.  
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Chapter 6: Discussion 
6.1 Economics 
Large-scale projects can have heavy impacts on the current market by revolutionizing the 
way an industry thinks and operates. Our project is still small scale, with our advisor being the 
main clientele. Since this device was developed for personal use in the Gaudette Lab, we do not 
foresee any direct economic impacts of our device. However, if this device is further developed 
and scaled-up in the future, it may influence the current market of drug screening methods.  
6.2 Environmental Impact 
Many projects for new products lead to environmental drawbacks based on materials and 
energy used. Our device was created to utilize materials and methods that are already present in 
labs to cut down on device cost and need for additional materials. For example, our device 
requires PDMS, a standard laboratory microscope, six-well plates, cell culture tools, cell media, 
and electrical stimulators, all of which are standard in most biological testing atmospheres. 
Additionally, the parts that our device requires for a lab to purchase are inexpensive and 
reusable, such as the molds for cantilever beams and anchor points, as well as the polycarbonate 
inserts. This way, few materials are wasted and our device can be used many times before 
additional purchasing is necessary. Overall, our device and testing procedures do not contribute 
to an adverse impact on the environment. If the philosophies applied by our project such as 
reusing already present laboratory methods and materials are applied to other testing systems, 
less harm can be done on the environment from creation of additional components, energy 
consumption, and unnecessary waste.  
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6.3 Social Influence 
With the progression of our device out of the prototype stage and into full clinical 
application, this product has the capability of benefiting numerous people. While pharmaceutical 
companies will have a more effective method for analyzing the cardiotoxicity of a theoretical 
drug, reducing the likelihood of marketing a harmful drug, the most significant impact will be 
seen on patients. During procedures and patient monitoring, the specific application of a drug 
and its side effects will be completely understood to prevent patient harm. This device would 
lead to fewer instances of unnecessary harm, and hopefully lead to the saving of patient lives. As 
this screening method becomes more and more effective, companies and other countries would 
take notice and seek out this product.   
6.4 Political Ramifications 
In addition to the obvious health and environmental impacts of a new product, it is also 
important to consider the political and legal ramifications of this device. Our screening device 
has the potential to have a sizable impact on the legal protection of pharmaceutical companies. 
Specifically, because the device is designed to allow for the earlier and more accurate detection 
of cardiotoxic compounds in a pre-clinical environment, there is a reduced chance of these 
harmful drugs reaching the market. In turn, there is a reduced chance of consumers developing 
heart conditions due to cardiotoxic drugs; therefore pharmaceutical companies are less likely to 
be sued for negligence after the withdrawal of a marketed drug. This ultimately prevents drug 
companies from losing large sums of money, which is important to have for drug development 
research and clinical trials. 
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6.5 Ethical Concerns 
With the creation of new testing methods, it is necessary to consider any ethical concerns 
that may provoke controversy surrounding the use of our device. After analysis of our device, the 
only possible ethical concern may be the use of stem cells. Throughout the years, with new 
biological testing methods and procedures, the controversy behind the use of stem cells has been 
in the forefront of the news. While our use of stem cells is solely for the use of modeling three-
dimensional heart structure and preventing cardiotoxicity in pharmaceutical agents, it is possible 
for a person to argue that the use of stem cells is still wrong. We are aware of this concern, 
however we utilized methods that were readily available and we feel that these cells are the 
optimal representation of cells in this application.  
6.6 Health and Safety 
If our device proves reliable and becomes commonplace in industry to detect cardiotoxic 
effects of pharmaceuticals, we could significantly reduce the number of faulty drugs that make it 
to clinical trials and the market. This could potentially save many people from unknown negative 
side effects, thus contributing to the overall health and safety of the population. If in vitro 
cardiotoxicity screening becomes faster and more reliable, potential life-saving drugs could be 
brought to market more quickly, having a positive impact on human health. 
6.7 Manufacturability 
Manufacturability is important to the success of any device or product. Our device was 
carefully designed to promote easy manufacturing and reproduction of all components. Our 
polycarbonate insert is easily machined, and our posts can be quickly and reliably produced 
using provided molds. The insert and molds were produced with computer-aided manufacturing 
on CNC machines, allowing for easy scalability to mass production. Disposable six-well plates 
58 
 
are readily available and very inexpensive, and because we use a standard laboratory microscope 
to obtain images, no proprietary imaging equipment is required. 
6.8 Sustainability 
Our device serves as a model for sustainability. We have designed our device such that 
the polycarbonate insert is completely reusable. We utilize PDMS posts that are non-toxic and 
require little effort to produce. Therefore, the production of our device has minimal negative 
impact on the environment and serves as a very sustainable solution to a cardiotoxic drug-
screening device. 
6.9 Conclusions 
 The microthread loading and fixation testing was conducted to make sure that our device 
could successfully hold a contracting cell-seeded fiber. The PDMS slit was the main focus of this 
study because the seeded thread was wrapped around the cantilever beam. We discovered that 
the slit on the PDMS anchor point could hold up to 0.1 to 0.15 N of force before the slit would 
fail and the seeded thread would slip. From previous research and calculations, we expected that 
a single cardiomyocyte produced approximately 2.37 nN of force (Nishimura, 2004). Based on 
this value and the calculations presented in Chapter 4, Section 5, we determined that our device 
could successfully hold a cell-seeded fiber without slipping.   
 The second testing procedure focused on the sterilization of components of the device. It 
was necessary for the components and reusable materials to be successfully sterilized to confirm 
biocompatibility for the use with the seeded microthreads. The removable anchor points and 
cantilever beams were successfully sterilized using the ethylene oxide gassing process. These 
parts only needed to be sterilized once because they would be thrown away afterwards. Because 
the gassing caused only slight swelling that did not affect their ability to function or fit in the 
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polycarbonate insert, we were able to conclude that sterilization would not adversely harm these 
device components. The other component, the polycarbonate insert had its sterility capabilities 
tested using the ethylene oxide gassing process and through the use of an autoclave. Neither of 
these sterilizing procedures adversely affected the polycarbonate insert, even after repeated 
sterilizations. Therefore, we knew that our insert could be used repeatedly because it could be 
sterilized multiple times without changing its properties.  
 The presence and status of cells seeded on the fibrin microthreads in our device were 
analyzed through two cell staining assays. The first was a Phalloidin/Hoechst stain. This study 
compared a freshly seeded fiber to a cell-seeded fiber that had spent three hours in our device. 
Both threads showed similar cell density and morphology, indicating that they had similar 
properties. The successful comparison of these two time points allowed the group to conclude 
that the loading process of placing seeded threads in our device did not lead to significant cell 
loss. This also allowed the team to conclude that up to three hours in our device would not cause 
cell loss on the fibrin microthreads.  
To analyze the health of the cells on the threads, a Live/Dead staining assay was 
conducted on a freshly cell-seeded microthread and a seeded microthread that had spent three 
hours in our device. The dead control showed numerous red dots for the dead panel indicating 
dead cells; while the overlay of the Hoechst stain confirmed that all of the present were indeed 
not alive. For the live experimental data, the live panel showed green color indicating that cells 
were alive. No red dots were seen in the dead panel, and in the overlay, the Hoechst stain 
matched up perfectly with the green color. This overlay indicated that all cells that were present 
were alive. These results showed that in comparison to the dead control, the thread that had spent 
three hours in our device had facilitated the cells residing on it and had not caused cell death. 
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Because of these cell-staining tests, we know that live cells can be maintained on the fibrin 
microthreads as they are suspended for periods of time in our device. In the future, we would like 
to conduct additional staining assays, in order to confirm the same quality for extended periods 
of time. However, for primary cell presence and quality testing, these results were promising.  
 The final testing was conducted on the ability to obtain contractile data using neonatal rat 
cardiomyocytes and our device. As stated in chapter five, this testing could not be concluded 
using the seeded threads that were provided. The main issue was that the seeded threads were 
immersed in media, in order to encourage some cell contraction before use. This immersion 
degraded the mechanical integrity of the seeded threads and when handled and loaded, these 
threads repeatedly broke. Before, when human mesenchymal stem cell seeded threads had been 
tested to solely observe if they could withstand the loading process, results had been 
encouraging. The seeded threads had been successfully loaded numerous times, so it seemed 
acceptable to assume that the neonatal rat cardiomyocytes seeded threads would have similar 
results. However, this was not the case and the team did not have the funds or time to test the 
neonatal rat cardiomyocytes again. Therefore, our team was not able to collect contractile data or 
video data. In the future, we would like to run additional tests using neonatal rat cardiomyocytes 
to obtain contractile data. Certain alterations would have to be conducted to produce these 
results, but based on our previous success and calculations, we expect our device can obtain this 
data.  
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Chapter 7: Final Design and Validation 
 
7.1 Final Design Description 
Our final design consists of three major components – a polycarbonate well plate insert, 
PDMS anchor points and cantilever beams, and cell-seeded fibrin microthreads. Together, these 
components can be used with a standard, disposable six well plate to quantify the force of 
contraction of the seeded cells on the fibrin microthreads. With the addition of pharmaceutical 
agents to the media, our device can be used to assess potential side effects of drugs on cardiac 
function.  
7.1.1 Polycarbonate Well Plate Insert 
 Our polycarbonate well plate insert was designed to work with most standard, disposable 
six well plates. To construct the insert, 1/16” thick polycarbonate was purchased from Ultimate 
Plastics in Worcester, MA. The plate was then cut in the Higgins Laboratory Machine Shop at 
WPI with the assistance of a machine shop technician. To assist in the manufacturing, the 
following CAD model was developed, as seen in Figure 7.1.   
 
Figure 7.1: CAD model of polycarbonate well plate insert 
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As shown in the figure, the overall dimensions of the plate are 12.05 cm x 7.60 cm. The 
plate contains twelve 0.5 x 0.5 cm square holes, two in each well. These cuts are made for the 
insertion of PDMS anchor points and cantilever beams. There are also 0.2 cm diameter circular 
holes, made for the insertion of electrical wires for the stimulation of fibrin microthreads. The 
plate has two chamfered edges so that it can fit in multiple designs of standard six well plates. 
Computer Aided Manufacturing (CAM) software was used in conjunction with a computer 
numerical control (CNC) mill in order to make the cuts in the polycarbonate.  
7.1.2 PDMS Anchor Points and Cantilever Beams 
 In order to suspend the fibrin microthreads in media within our device and be able to 
measure the contraction of the threads, we designed both PDMS anchor points and cantilever 
beams. PDMS is a soft, thermoset plastic, that is made by combining two liquid components into 
a mold in the desired shape. Using CAD software, we designed two aluminum molds for the 
purpose of creating the anchor points and cantilever beams, as seen in Figures 7.2 a, b, and c.  
 
63 
 
a) b) 
c) 
Figure 7.2: Complete molds for anchor points (a), cantilever beams (b), and half of the two-part anchor point mold (c) 
As seen in Figure 7.2, each mold consists of six different wells for the insertion of PDMS 
so that one well plate insert can be completed with the preparation of one mold. Each mold is a 
two-part mold, as displayed in Figure 7.2c, so that the PDMS can be easily removed after it is 
poured. Each mold also has slits on the side in order to easily pull them apart to remove the 
PDMS. Figure 7.2a shows the anchor point mold. The total depth of the well is 1.85875 cm. The 
anchor point portion of the well measures 0.5 cm x 0.5 cm and is designed so that it protrudes 1.5 
cm out from the polycarbonate well plate insert. In order to keep the anchor point from falling 
through the well plate, a thin layer was added to the top that measures 0.75 cm x 0.75 cm. Figure 
7.2b shows the cantilever beam mold, which is designed with the same dimensions as the anchor 
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point mold, except that the cantilever beam portion of the mold is circular, with a diameter of 
.238 cm.  
The molds were constructed out of aluminum. CAM software was used in conjunction 
with a CNC mill in WPI’s Higgins Laboratory Machine Shop in order to make the proper cuts in 
the aluminum. Assistance was received from a trained machine shop technician. Directions for 
using the molds to create the PDMS anchor points and cantilever beams are found in Appendix 
E.   
The entire assembly appears as below in Figure 7.3:  
 
Figure 7.3: Completed assembly showing polycarbonate insert with PDMS anchor points and cantilever beams housed 
inside a standard, disposable six well plate 
 
7.1.3 Cell-Seeded Fibrin Microthreads 
 Individual fibrin microthreads were provided by the Gaudette Lab and then bundled into 
groups of eight and cut to lengths of about 6-7 cm. To perform testing for our device, these 
microthreads were seeded with neonatal rat cardiomyocytes. The protocols for bundling and 
seeding the threads are found in Appendix E.  
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7.2 Loading of the Device 
After the threads are seeded, they can be loaded into the device. It is important that the 
threads are loaded immediately after the seeding process is finished so that they maintain their 
mechanical properties during the process. The protocol for loading the loading process is also 
found in Appendix E. 
7.3 Imaging of Contraction 
 Once the threads have been successfully loaded into the device, the assembly should be 
placed in a cell incubator. The threads will likely be ideal for imaging contracting about 48 hours 
after the seeding process is complete. Microthreads seeded with neonatal rat cardiomyocytes can 
contract spontaneously or with the aid of electrical stimulation. When the threads are ideal for 
contraction, they can be imaged using a standard laboratory microscope. The protocol for this 
process is found in Appendix E.  
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Chapter 8: Conclusions and Recommendations 
Our device shows great promise in providing a method to quickly, reliably, and easily 
evaluate the contractile force and rate of cardiac cell-seeded fibers in vitro. Through validation 
testing, we have demonstrated our device’s ability to reliably hold fibrin bundles without 
slipping or breaking, maintain cell viability for at least three hours, and allow for the capture of 
very high quality images and video. Although we were not able to conduct contractile tests using 
cardiac cell-seeded fibers in our device, our research and calculations suggest that the PDMS 
cantilever beams will deflect a distance that is easily detectable by a microscope. Composed 
primarily of polycarbonate and PDMS, our device is very cost effective, and all materials can be 
easily replaced or reproduced. Additionally, the design minimizes external costs by being 
compatible with standard disposable six-well plates and by reducing the amount of media 
required in each well. Finally, our device is highly user-friendly because the polycarbonate insert 
exhibits a unique inverted design that is removable from the six-well plate, allowing the user 
more room to easily secure the cell-seeded threads in the attachment system. 
While we were successful in developing a proof-of-concept device that holds much 
promise in being used as a drug-screening platform, we were unable to definitively validate this 
proof of concept due to time and financial constraints. We recommend additional tests and design 
improvements before the device may be used in a pre-clinical environment. First, developments 
must be made toward improving the integrity and contractile strength of the cardiomyocyte-
seeded fibrin bundle constructs. Further biocompatibility tests should be conducted to quantify 
and analyze the morphology, density, and uniformity of cells seeded on the fibrin bundles so that 
improvements in the fibrin bundle cell seeding process can be made. Additionally, electrical 
stimulation of cardiomyocyte-seeded fibers within our device should be performed to pace the 
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cells on the threads to promote a strong, uniform contraction of the bundle suitable for evaluation 
and testing. Once the attachment and qualitative evaluation of contracting cardiac cell-seeded 
fibers is achieved using our design, we suggfest the implementation of software to be used in 
conjunction with our device in order to present a quantitative output of contractile rate and force 
exhibited by the fibers. Upon future testing of various pharmaceutical agents with our device, a 
numerical and graphical representation of contractile data in comparison with control data would 
ensure the quick and easy identification of potentially harmful compounds on the heart. 
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Glossary 
 
Bundle – A group of 4-12 fibrin microthreads that are twisted together. 
 
Cantilever Beam – A structure that is anchored only at one end. A tissue can be attached to a 
cantilever beam in order to calculate exerted force by monitoring displacement.  
 
Cardiotoxicity – The occurrence of cardiac physiological or muscular damage due to 
medication. 
 
Fibrin Microthreads – WPI patented extruded protein fiber that is created using fibrinogen and 
thrombin. These threads are used in cell testing because they replicate a three-dimensional 
structure. This application is especially valuable in the field of cardiac testing.  
 
hMSCs – A type of cells commonly used in cell testing because they exhibit properties of cells 
present in the human body.  
 
Limit Switch – An off and on switch used in circuitry to implement a stop condition for 
evaluating an electrical signal.  
 
PDMS – Polydimethylsiloxane (PDMS) is a silicone-based rubber that is created by mixing an 
elastomer base and curing agent. It is commonly found in laboratories, which is used for cellular 
testing because of its known biocompatibility.  
 
Polycarbonate – A thermoplastic polymer that is durable with low-scratch resistance and is 
easily workable. Polycarbonate was the material selected for the insert in our device.   
 
Suture – A fibrin microthread bundle that is folded through a surgical needle for use in cardiac 
cell therapy.  
 
Transducer – A sensor used to compute energy and output a resulting measure. In this project, a 
force transducer was considered as a method for measuring contractile force of the seeded fibrin 
microthread.  
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Appendix A: Microthread Extrusion and Seeding Procedure 
THREAD EXTRUSION AND BUNDLING 
1. Combine 70mg/mL fibrinogen in HEPES-buffered saline (HBS) and 6U/mL thrombin in 
40mM CaCl2 using blending connector (figure 1). 
2. Extrude protein blend at a constant rate of 4.25mm/min through small diameter 
polyethylene tubing into shallow 10mM HBS bath (pH 7.4). 
 
3. Remove extruded threads from HBS bath and stretch across hollow cardboard box or 
equivalent. Allow to air-dry overnight. 
4. Rehydrate threads and twist together to form bundles. Bundles vary between four to 
twenty-four, with eight to ten being most common. 
5. Stretch bundles and allow to air-dry overnight. 
6. Store in desiccators until needed. 
 
CELL SEEDING 
1. Using surgical scissors, cut bundle into desired length (typically 4cm). 
2. Place thread inside small diameter polyethylene tubing (i.d. ~2mm). Clamp off both ends 
of tube. 
3. Using a syringe, inject media containing cells through one end of the tube, filling the tube 
and completely submerging the fibrin bundle. 
4. Place setup in a 50mL conical tube. 
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5. Load conical tube in rotator and rotate on a 15 degree incline at 8rpm for 1-2 days. 
 
 
Cornwell, K., Pins, G., Billiar, K. “Collagen and Fibrin Microthreads In A Discrete Thread 
Model of In Vitro ACL Scaffold Regeneration”. Duane Morris LLP - Patent US2011/0034388 
A1. (Feb 10, 2011).  
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Appendix B: Pairwise Comparison Chart 
 
 
PRIMARY 
OBJECTIVE 
Biocompatible HTS 
 
Safe for 
User 
Easy to 
Use 
Cost 
Effective 
Total 
Biocompatible  0 1 1 1 3 
HTS 1  1 1 1 4 
Safe for User 0 0  0 1 1 
Easy to Use 0 0 1  1 2 
Cost Effective 0 0 0 0  0 
 
 
 
  
75 
 
Appendix C: Work Breakdown Structure 
Design a HTS Device for 
Detection of Pharmaceutical 
Side-Effiects on Cell-Seeded 
Fiber
Understand client 
requirements
Clarify client statement
Meet with Client
Revise client statement
Perform Research
Cardiac Biology
Cardiotoxicity
Microthread System
Current Methods
Develop Ranked Objectives
Pairwise Comparison Chart
Review with Client
Revise Objectives
Analyze Function 
Requirements
Develop Functions
Functions- Means Tree
Generate Design Alternatives
Brainstorm ideas
Match means to functions
Develop List of Design 
Alternatives
Evaluate Alternatives
Weight Objectives
Design Evaluation Matrix
Rank Alternatives
Select Best Alternative
Select Preliminary Design
Review with client
Construct Prototype
CAD Models
Order Materials
Construct
Testing
Revisions
Document Process
Keep updated lab notebook
Draft first drafts of report
Revise with client
Final Report
Final Presentation
Project Management
Hold weekly meetings
Review progress
Set termly goals
Develop and use Gantt Chart
76 
 
Appendix D: Quarterly Gantt Charts 
 
First Quarter 
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Second Quarter 
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Third Quarter 
 
 
 
Fourth Quarter 
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Appendix E: Laboratory Protocols 
 
Protocol for Seeding Fibrin Microthreads  
 
Materials: 
 Sterile thread-bundle in Bioreactor 
 Sterile PBS 
 Sterile 1 mL syringe (3) 
 Cell Suspension (100,000 cells/100 µL) 
 50 mL conical tube 
 Tube rotator (fully charged!) 
Procedure: 
1. Use a sterile syringe to inject sterile PBS into bioreactor (by attaching syringe to the 
already inserted 27G needle). 
2. Ensure all bubbles are eliminated from the bioreactor. 
3. Attach slide clamp and remove/discard syringe. (Keep syringe needle in the bioreactor). 
4. Allow 20 min for hydration 
5. While bundle hydrates prepare cell suspension according to cell passaging protocol 
6. Use new syringe to expel all sterile PBS from the bioreactor before seeding. For this, 
remove the slide clamp at the end opposite to the needle, draw air into a new sterile 
syringe and push the air into the bioreactor to expel all the PBS.  
7. Use a new syringe (1 cc maximum) to inject cell suspension (100,000 cells / 100 µL) into 
the bioreactor. For this, hold the bioreactor such that the open end of the bioreactor (one 
without slide clamp) remains elevated such that the cell suspension doesn’t spill out 
while being injected.  After 100 µL of cell suspension is injected into the bioreactor, 
close the end opposite the needle by sliding the clamp onto the tubing. 
8. After injecting the cell suspension and adding the slide clamp, remove the 27G needle 
from the bioreactor. 
9. Place the bioreactor into a gas permeable 50 mL conical tube. 
10. Place the bioreactor into the MACSmix tube rotator and rotate at 4 RPM (lowest setting) 
for 24 hours. 
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Protocol for Phalloidin/Hoechst Staining  
 
Reagents: 
 Phosphate Buffered Saline 
 4% Paraformaldehyde (Only needed for tissues/cells that have not been fixed); 
 0.25% Triton-X 
o 0.25% V/V  Triton-X in PBS 
o 10 μL Triton-X in 3990 μL PBS 
 1% BSA 
o 1% V (W)/V BSA in PBS 
o 40 μL in 3960 μL PBS 
 Phalloidin (AF 488 Phalloidin A12379, Invitrogen) 
o 2.5% V/V Phalloidin in PBS 
o 50 μL in 1950 μL 
 Hoechst 
o 0.0167% Hoechst dye in PBS 
o 0.5 μL in 3000 μL PBS 
 
For unfixed sections/cells: 
1. Rinse in PBS x2 
2. Fix in 4% Paraformaldehyde for 10 minutes 
3. Follow directions for fixed sections 
 
For fixed sections/cells: 
1. Rinse with PBS x2 
2. Triton-X solution for 10 minutes 
3. Rinse with PBS x2 
4. Block with BSA solution for 30 minutes 
5. Phalloidin solution for 30 minutes 
6. Rinse with PBS x2 
7. Hoechst solution for 3-5 minutes (typically 3) 
8. Rinse with PBS x2 
9. Cytoseal and coverslip 
10. Store frozen at -20 degrees C. 
Results: 
 F-actin is stained green 
 Nucleus is stained Blue 
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Protocol for Live/Dead Assay 
 
Solutions: 
 
Solution 1: 
1.0 mL Serum Free DMEM 
1.0 μL Ethidium Homodimer-1 
1.0 μL Calcein AM 
 
Solution 2: 
1.0 mL Serum Free DMEM 
1.0 μL Ethidium Homodimer-1 
1.0 μL Calcein AM 
0.5 μL Hoechst Dye 
 
Concentrations: 
300 μL/thread 
 
Process: 
Incubate dead controls in 70% Ethanol for 30 minutes prior to experiment 
Mix solution 1 within 1 hour of use 
Incubate cells with solution 1 for 15 minutes 
Mix solution 2 within 1 hour of use 
Incubate cells in solution 2 for 15 minutes 
Wash cells with 1x PBS 6 times 
Fix cells in 4% Phosphate buffered formaldehyde for 10 minutes 
Mount and coverslip cells on an uncharged microscope slide 
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Protocol for PDMS anchor points and cantilever beams to prepare well plate insert 
 
Materials: 
1. Sylgard Silicone Elastomer base (Ellsworth Adhesive #184 SYL ELAST) 
2. Sylgard Silicone Elastomer curing agent (Ellsworth Adhesive #184 SYL ELAST) 
3. Gloves 
4. Spatula 
5. Weigh dish 
6. Scale 
7. PDMS molds – for anchor points and cantilever beams  
8. Clamps  
9. Oven 
10. Teasing needle w/ wooden handle 
11. Well plate insert 
 
Methods: 
1. Before mixing the PDMS, use two clamps on each mold to ensure that the pieces of the 
mold are tightly held together and the PDMS will not leak out, as shown in the picture 
below: 
 
2. Mixing and Pouring PDMS 
a. Wearing gloves, weigh 8 ounces Sylgard silicone elastomer base and 0.8 ounces 
Sylgard silicone elastomer curing agent. Note: do not mix the stock solutions!!! 
Use separate weighing materials for each reagent. 
b. Pour reagents together and thoroughly mix the elastomer base and curing agent 
with a spatula. 
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c. Using the spatula, pour the well-mixed solution into each of the two molds. Fill 
each mold to just below the top, as the PDMS expands upon heating. 
d. Degas the PDMS by putting it into a vacuum chamber for 1 hour. 
e. After degassing, visually inspect the PDMS to ensure that there are no more 
bubbles. If there are, repeat steps 2d and 2e. 
f. Cure the PDMS by placing the molds into an oven set to 60ºC for 1 hour on a 
sheet of aluminum foil.  
g. Remove the molds from the oven being careful to only touch the aluminum foil. 
h. Let the molds sit for 24 hours. 
 
3. Removing the PDMS from the molds 
a. Examine the top of the mold. If PDMS has dried on the top layer of the mold, use 
a teasing needle to gently remove the excess PDMS.  
b. Use a flat head screwdriver to pull apart the two molds by applying pressure to 
the notch cut out on each side of the top of the mold.  
c. Remove each anchor point or cantilever beam individually. 
d. Clear off any extra thin film of PDMS by gently removing it with your hands or 
with the assistance of a teasing needle.  
 
4. Insert each PDMS piece into the corresponding opening in the well plate insert, as seen 
below. Each anchor point and cantilever beam should fit securely within its 
corresponding hole in the polycarbonate insert.  
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Protocol for Loading Microthreads in the Device 
  
Materials:  
1. Polycarbonate insert with pre-loaded PDMS anchor points and cantilever beams   
2. Packaged, disposable six well plate  
3. Razor blade 
4. Cell-seeded fibrin microthreads in media 
5. Fine-tipped forceps (2)  
6. Gloves 
7. Ruler 
8. Marker 
9. Eye dropper 
10. Media 
11. Automatic pipette  
Methods: 
1. Prior to the loading process, ensure that all materials are sterile and that all steps of the 
following procedure are completed in a sterile fume hood. The insert and PDMS should 
be sterilized with ethylene oxide gas. All other materials can be sterilized with 70% ethyl 
alcohol before being placed in the fume hood.  
2. Remove the disposable six well plate from the package and fill each well with 5 mL of 
media with the use of the automatic pipette. Replace the lid upon completion.  
3. Using a ruler and marker, draw a line 0.1 cm from the top of both the PDMS anchor point 
and cantilever beam.  
4. Using a razor blade, cut a slit down the middle of the top face of the anchor point, as 
shown below, to the 0.1 cm depth identified by the marker line. 
 
 
5. Again using the razor blade, cut a horizontal notch at the marker line in the cantilever 
beam, as shown here.  
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6. Repeat steps 2-4 for each necessary pair of anchor points and cantilever beams.  
7. Place the polycarbonate insert in its inverted orientation so that the anchor points and 
cantilever beams can be easily accessed.  
8. Remove a fibrin microthread from a petri dish by grasping it at one end with the forceps.  
9. Using both pairs of forceps, insert this end of the microthread into the vertical slit in the 
anchor point with a careful, flossing action.  
10. Grasp the other end of the thread and wrap it around the cantilver beam so that the middle 
of the thread rests in the horizontal slit.  
11. Repeat step 7 with the other end of the thread.  
12. If the microthread is not taut, use the forceps to pull each end of the thread through the 
anchor point until it is tight, while ensuring the cantilver beam is still perfectly upright. A 
correctly loaded microthread should appear as below:  
 
 
` 
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13. Repeat steps 7-11 for the necessary amount of threads. (Media may need to be 
periodically added to the loaded threads to prevent them from drying out. This can be 
done with the eyedropper and the excess media from the petri dish.)  
14. Once all loading is complete, remove the lid of the six well plate and place the insert on 
the plate so that the microthreads are immersed in media. Replace the lid of the six well 
plate.  
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Protocol for Imaging the Microthreads in the Device 
 
Materials: 
1. Well plate and insert assembly with loaded microthreads 
2. Laboratory microscope with video imaging capabilities 
3. Grass stimulator 
4. Computer 
Methods: 
1. Place the six well plate with the contained loaded microthreads on the microscope 
platform so that the appropriate well is seen in the scope.  
2. If imaging the thread itself, travel along the length of the thread with the scope until a 
section of contracting fiber is visible. This contraction can be recorded with the use of a 
Fastec HiSpec4 4G camera and Matlab script to obtain AVI files.   
3. To obtain quantifiable contraction data, image the cantilever beam by moving the well 
plate until the cantilever beam is in view. Record a video of the deflecting cantilever 
beam using a Fastec HiSpec4 4G camera and Matlab script to obtain AVI files. The 
deflection can be used to calculate the force of the microthread as described in Chapter 5.  
4. For electrical stimulation of the microthreads: 
a. Remove the lid of the six well plate.  
b. Insert an electrode into each of the two circular holes in the polycarbonate 
insert so that an electrode touches each end of the loaded microthread.  
c. Replace the lid on top of the six well plate. 
d. Adjust the settings on the Grass stimulator to obtain the desired voltage, 
frequency, etc.  
e. Image the thread and cantilever beam as described in steps 2 and 3. The 
correct set up can be seen in the image below:  
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Appendix F: Staining Images 
 
Phalloidin/Hoechst Stains 
 
Time = 0 (10X) 
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Time = 0 (20X) 
 
Time = 3 hours (10X) 
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Time = 3 hours (20X) 
 
Time = 3 hours (20X) 
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Live/Dead Assay 
 
Time = 0 (Dead Control, 10X) 
 
Time = 3 hours (Dead Control, 10X) 
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Time = 0 (Experimental, 10X) 
 
Time = 3 hours (Experimental, 10X) 
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Time = 3 hours (Experimental, 20X) 
 
Time = 3 hours (Experimental, 20X) 
